We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Lenabasum

News List

Potential Cystic Fibrosis Treatment Does Not Meet Primary Endpoint americanpharmaceuticalreview
October 10, 2020
Corbus Pharmaceuticals announced topline results from its 28-week Phase 2b study of lenabasum in patients with cystic fibrosis (CF).
Lenabasum Study for Systemic Sclerosis Does Not Meet Primary Endpoint americanpharmaceuticalreview
September 23, 2020
Corbus Pharmaceuticals has announced topline results from the 52-week Phase 3 RESOLVE-1 study of lenabasum in patients with diffuse cutaneous systemic sclerosis (SSc). SSc is a rare and life-threatening multi-system autoimmune disease for which there ...
Corbus Pharmaceuticals Announces Appointment of Craig Millian as Chief Commercial Officer firstwordpharma
March 06, 2019
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”) today announced the appointment of Craig Millian as Chief Commercial Officer, effective February 28, 2019. Mr. Millian will develop and drive U.S. ..